

Case Worksheets for Newborn Screening

Last Updated: April 22, 2025



Case Information Worksheet: Information Collected for ALL Cases

Infant Demographic Information		
State Unique ID? (alphanumeric)* A state unique ID is a number and or letters that your program provides to tag or track each confirmed case and update information as needed. Gestational Age? (in weeks) Birth Information Date of Birth? (mm/dd/yyyy)*	Unique IDs should only include numbers, letters, hyphens, and underscores	
Time (hh:mm AM/PM) If time of birth is not available, only enter the date		
Year* Year of birth is stored to calculate Quality Indicators	Automatically populated based on date of birth	
Birth Weight? (in grams)		
Biological Sex?	☐ Male☐ Female☐ Unspecified☐ Unknown	
Race? (Select all that apply)	 □ White □ Black or African American □ American Indian or Alaskan Native □ Asian □ Native Hawaiian or other Pacific Islander □ Not Reported □ Unknown 	
Ethnicity?	 ☐ Hispanic, Latino(a) or Spanish origin ☐ Not of Hispanic, Latino(a), or Spanish origin ☐ Not Reported ☐ Unknown 	
Screening Information		
Which newborn screen result indicated this infant was at risk for the disorder?	☐ Initial Screen ☐ Subsequent Screen ☐ Second Required Screen	
Was prenatal testing done that indicated that this infant was at risk for this disorder?	☐ Yes ☐ No ☐ Unknown	
Was there family history that indicated that this infant was at risk for this disorder?	☐ Yes ☐ No	



	□ Unknown
Maria de Carlo de Calabra de Carlo de C	□ Yes
Was this individual identified outside of the	□ No
newborn screening?	□ Unknown
	☐ Parental Refusal
	☐ Lost to follow-up after
	unsatisfactory specimen
What was the reason the infant was missed?	☐ Biologic false negative/result within
(IF individual was identified outside of	normal range
newborn screening = Yes)	☐ Did not have valid screen due to
	error
	☐ Other (please describe below)
Initial & Subsequent Speci	men Collection Information
Specimen Collection	
Date of specimen collection (mm/dd/yyyy)?	
Time (hh:mm AM/PM)	
	Automatically calculated from birth and
Time Elapsed Since Birth (in hours)	specimen collection dates; some states
,	can enter directly
Receipt by Lab	
Date of receipt by lab (mm/dd/yyyy)?	
Time (hh:mm AM/PM)	
, , , , ,	Automatically calculated from birth and
Time Elapsed Since Birth (in days)	receipt date; some states can enter
. , , ,	directly
Release of Out-of-Range Results	
Date of release of out-of-range results	
(mm/dd/yyyy)?	
Time (hh:mm AM/PM)	
	Automatically calculated from birth and
Time Elapsed Since Birth (in days)	report date; some states can enter
	directly
Intervention, Follow-	up, and Diagnosis
Intervention by Appropriate Medical Provider	
Date of intervention by appropriate medical	
provider (mm/dd/yyyy)?	
Time (hh:mm AM/PM)	
	Automatically calculated from birth and
Time Elapsed Since Birth (in days)	intervention date; some states can enter
	directly
Confirmation of Diagnosis	
Date of confirmation of diagnosis	
(mm/dd/yyyy)?	



Time (hh:mm AM/PM)	
Time Elapsed Since Birth (in days)	Automatically calculated from birth and diagnosis date; some states can enter directly
Is infant receiving treatment/care out-of-state?	☐ Yes; enter where state receives care ☐ No ☐ Unknown
Is this diagnosis reversed (does not refer to the therapeutic interventions to address a condition (i.e., surgery, treatment, therapy, etc.)	☐ Yes; enter Year diagnosis reversed☐ No☐ Unknown



Newborn Screening Surveillance Case Definitions:

Case Confirmatory Diagnosis Follow-Up

Developed by the Health Resources and Services Administration (HRSA) and NewSTEPs in cooperation with the newborn screening medical sub-specialty community, standard surveillance case definitions for newborn screening conditions allow for the determination of true prevalence and incidence of disorders, and for comparison of outcomes across states. The case definition forms can be found in the pages to follow, stratified by disorder type. Additionally, you can find case definition classification tables <u>linked here</u> that can be used as a reference resource.

Table of Contents

Metabolic Disorders	7
Organic Acid Disorders	7
Glutaric Acidemia/ Aciduria Type I (GA1)	7
Holocarboxylase Synthetase (Multiple Carboxylase) Deficiency (MCD) or Other Biotin Disorders	9
Isovaleric Acidemia/ Aciduria (IVA)	11
3- Methylcrotonyl-CoA Carboxylase Deficiency (3-MCC)	13
Propionic Acidemia/ Aciduria (PROP)	15
Methylmalonic Acidemia (methylmalonyl-CoA mutase; MUT)	17
Methylmalonic Acidemia (cobalamin disorders; Cbl A, Cbl B, Cbl Dv2)	19
Methylmalonic Acidemia with Homocystinuria (Cbl C, Cbl D, Cbl F, Cbl Dv1, Cbl J)	21
Fatty Acid Disorders	23
Primary Carnitine Deficiency/ Carnitine Uptake Deficiency (CUD)	23
Medium-chain acyl-CoA Dehydrogenase Deficiency (MCAD)	25
Tri Functional Protein Deficiency (TFP)	27
Long-chain L-3 Hydroxyacyl-CoA Dehydrogenase Deficiency (LCHAD)	29
Very Long-chain acyl-CoA Dehydrogenase Deficiency (VLCAD)	31
Amino Acid Disorders	33
Argininosuccinic Acidemia/ Aciduria (ASA)	33
Citrullinemia, Type I (CIT)	35
Homocystinuria (Cystathionine Beta-Synthase (CBS) Deficiency; HCY)	39
Maple Syrup Urine Disease (MSUD)	41
Tyrosinemia Type I (TYR-1)	44
Endocrine Disorders	46
Congenital Hypothyroidism (CH)	46

	Congenital Adrenal Hyperplasia (CAH)	48 NewSTEPs
Hem	Congenital Adrenal Hyperplasia (CAH) noglobinopathies	A Program of the Association of Public Haytri Laboratories*
	Presence of Hb S	51
	Presence of Other Hb Variant	54
Lyso	somal Storage Disorders	57
	Mucopolysaccharidosis Type I (MPS I)	57
	Pompe Disease	59
Othe	er Disorders	62
	Biotinidase Deficiency (BIOT)	62
	Galactosemia (GALT)	63
	Cystic Fibrosis	65
	Severe Combined Immunodeficiencies (SCID)	70
	Critical Congenital Heart Disease (CCHD)	73
	X-Linked Adrenoleukodystrophy (X-ALD)	76
	Spinal Muscular Atrophy (SMA)	81

Note: standard surveillance case definitions have not been developed for 3-Hydroxy-3-methyglutaric aciduria (HMG), ß-Ketothiolase deficiency (ßKT), Mucopolysaccharidosis Type II (MPS II), Guanidinoacetate methyltransferase deficiency (GAMT) and Infantile Krabbe Disease (Krabbe). These are forthcoming.



Metabolic Disorders

Organic Acid Disorders

Glutaric Acidemia/ Aciduria Type I (GA1)

Enz	ymatic
Were urine organic acids tested? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was 3-OH Glutaric acid level □ Elevated □ Normal □ Unknown Was Glutaric acid level □ Elevated □ Normal □ Unknown
Were serum organic acids tested? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was 3-OH Glutaric acid level □ Elevated □ Normal □ Unknown Was Glutaric acid level □ Elevated □ Normal □ Unknown
Were plasma acylcarnitines tested? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was C5 -DC level □ Elevated □ Normal □ Unknown
Was enzyme analysis for Glutaric Acidemia enzyme activity completed? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was enzyme activity: □ Consistent with disease □ Normal activity (not consistent with disease) □ Unknown
Molecular Genetics	



[IF YES] What genes were included in the mutation analysis? (select all that apply) □ GCDH
Other gene:
[For each gene selected]
Check the types of variants found on:
Allele 1: ☐ Variant known to be disease causing ☐ Variant of unknown significance ☐ Variant of unknown significance (predicted to be pathogenic) ☐ Wild Type (Normal) ☐ Unknown
Allele 2: ☐ Variant known to be disease causing ☐ Variant of unknown significance ☐ Variant of unknown significance (predicted to be pathogenic) ☐ Wild Type (Normal) ☐ Unknown

Holocarboxylase Synthetase (Multiple Carboxylase) Deficiency (MCD) or Other Biotin Disorders

*Not Biotindase Deficiency

	Other Biotin Disorder (not biotindase deficiency)	
	Jnknown	
		ymatic
	e urine organic acids tested?	[IF YES]
	Yes No	Was 3OH Isovaleric acid level:
	Unknown	☐ Elevated
_ `	OTIMIOWIT	□ Normal
		☐ Unknown
		Was 3OH Propionic acid level:
		☐ Elevated
		□ Normal
		☐ Unknown
		Was 3-methylcrotonyl glycine level:
		☐ Elevated
		□ Normal
		☐ Unknown
Wer	e plasma acylcarnitines tested?	[IF YES]
	Yes	Was C3 level
	No	□ Elevated
	Unknown	□ Normal
		☐ Unknown
		Was C5-OH level
		□ Elevated
		□ Normal
		☐ Unknown

Were infant chemistries (biotinidase) studies completed? ☐ Yes ☐ No ☐ Unknown	[IF YES] Were infant chemistries (biotinidase) studies: □ Normal □ Abnormal □ Unknown
NAVA a a a a a a a a a a a a a a a a a a	[IF VFC]
Was enzyme analysis for holocarboxylase synthetase deficiency enzyme activity	[IF YES]
completed?	Was enzyme activity:
☐ Yes	Consistent with disease
□ No	□ Normal activity (not consistent with disease)□ Unknown
□ Unknown	O O O O O O O O O O O O O O O O O O O
Molecul	ar Genetics
Was a mutation analysis done? ☐ Yes	[IF YES]
□ No	What genes were included in the mutation analysis?
□ Unknown	(select all that apply)
	□ HLCS
	Other gene:

[For each gene selected]
Check the types of variants found on:
Allele 1:
☐ Variant known to be disease causing
☐ Variant of unknown significance
 Variant of unknown significance (predicted to be pathogenic)
□ Wild Type (Normal)
Unknown
- Onknown
Allele 2:
☐ Variant known to be disease causing
☐ Variant of unknown significance
☐ Variant of unknown significance (predicted to
be pathogenic)
☐ Wild Type (Normal)
□ Unknown

Isovaleric Acidemia/ Aciduria (IVA)

 Final Diagnosis as determined by clinician performing follow-up: ☐ Isovaleric Acidemia/ Aciduria (IVA) ☐ Short/branched chain acyl-CoA dehydrogenase Deficiency (SBCAD) or 2-methylbutyrl CoA dehydrogenase deficiency ☐ Unknown 		
Enz	ymatic	
Were urine organic acids tested? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was 3OH Isovaleric acid level □ Elevated □ Normal □ Unknown Was Isovaleryl glycine level □ Elevated □ Normal □ Unknown	
Were plasma acylcarnitines tested? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was C5 -DC level □ Elevated □ Normal □ Unknown	
Was enzyme analysis for Glutaric Acidemia enzyme activity completed? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was enzyme activity: □ Consistent with disease □ Normal activity (not consistent with disease) □ Unknown	
Molecular Genetics		
Was a mutation analysis done? ☐ Yes ☐ No ☐ Unknown	[IF YES] What genes were included in the mutation analysis? (select all that apply) □ IVD □ Other gene:	

[For each gene selected]
Check the types of variants found on:
Allele 1: □ Variant known to be disease causing □ Variant of unknown significance □ Variant of unknown significance (predicted to be pathogenic) □ Wild Type (Normal) □ Unknown
Allele 2: ☐ Variant known to be disease causing ☐ Variant of unknown significance ☐ Variant of unknown significance (predicted to be pathogenic) ☐ Wild Type (Normal) ☐ Unknown

3-Methylcrotonyl-CoA Carboxylase Deficiency (3-MCC) Final Diagnosis as determined by clinician performing follow-up:

 In a Diagnosis as determined by clinician performing follow-up: 3-Methylcrotonyl-CoA Carboxylase Deficiency (3-MCC) Maternal MCC deficiency MT-ATP6 related mitochondrial disorders 	
Unknown	matic
Were urine organic acids tested? ☐ Yes ☐ No ☐ Unknown	ymatic [IF YES] Was 3OH Isovaleric acid level □ Elevated □ Normal □ Unknown Was 3-methylcrotonyl glycine level
	☐ Elevated ☐ Normal ☐ Unknown
Were plasma acylcarnitines tested? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was C5 -OH level □ Elevated □ Normal □ Unknown
Was maternal 3-MCC level tested and ruled out? ☐ Yes ☐ No ☐ Unknown	
Was enzyme analysis for 3-MCC enzyme activity completed? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was enzyme activity: □ Consistent with disease □ Normal activity (not consistent with disease) □ Unknown
Molecular Genetics	
Was a mutation analysis done? ☐ Yes ☐ No ☐ Unknown	[IF YES] What genes were included in the mutation analysis? (select all that apply) □ MCCC1 □ MCCC2 □ Other gene:

[For each gene selected]
Check the types of variants found on:
Allele 1: □ Variant known to be disease causing □ Variant of unknown significance □ Variant of unknown significance (predicted to be pathogenic) □ Wild Type (Normal) □ Unknown
Allele 2: ☐ Variant known to be disease causing ☐ Variant of unknown significance ☐ Variant of unknown significance (predicted to be pathogenic) ☐ Wild Type (Normal) ☐ Unknown

Propionic Acidemia/ Aciduria (PROP)

Final Diagnosis as determined by clinician performing follow-up:

l Propionic Acidemia (PROP) l Maternal vitamin B12 deficiency l Succinate-CoA ligase deficiency l Unknown	
	zymatic
ere urine organic acids tested? Yes No Unknown	[IF YES] Please indicate which of the following metabolites were detected:
	Propionyl glycine? Yes No Unknown
	Tiglyglycine? Yes No Unknown
	Methylcitrate? □ Yes □ No □ Unknown
	3OH Propionic acid level? ☐ Yes ☐ No ☐ Unknown
	MMA? Yes No Unknown
	Methylcrotonyl glycine? ☐ Yes ☐ No ☐ Unknown

We	ere plasma acylcarnitines tested?	[IF YES]
	Yes	Was C3 level:
	No	□ Elevated
	Unknown	□ Normal
		☐ Unknown
	Molecu	lar Genetics
Wa	as a mutation analysis done?	[IF YES]
	Yes	What genes were included in the mutation
	No	analysis? (select all that apply)
	Unknown	□ PCCA
		□ PCCB
		☐ Other gene:
		[For each gene selected]
		Check the types of variants found on:
		Allele 1:
		☐ Variant known to be disease causing
		☐ Variant of unknown significance
		☐ Variant of unknown significance (predicted to
		be pathogenic)
		☐ Wild Type (Normal)
		☐ Unknown
		Allele 2:
		☐ Variant known to be disease causing
		☐ Variant of unknown significance
		☐ Variant of unknown significance (predicted to
		be pathogenic)
		☐ Wild Type (Normal)
		☐ Unknown

Methylmalonic Acidemia (methylmalonyl-CoA mutase; MUT) Final Diagnosis as determined by metabolic geneticist or clinician performing follow-up: ☐ Mutase(-) (mut-) ☐ Mutase (0) (mut0) ☐ Maternal vitamin B12 deficiency ☐ Succinate-CoA ligase deficiency ☐ Unclassified ☐ Unknown	
	ymatic
Was serum MMA level tested? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was MMA level in serum: □ Elevated □ Normal □ Unknown
Was urine MMA level tested? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was MMA level in urine: □ Elevated □ Normal □ Unknown
Were plasma acylcarnitines tested? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was C3 level □ Elevated □ Normal □ Unknown
Was maternal vitamin B12 levels tested? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was maternal vitamin B12 deficient? ☐ Yes ☐ No ☐ Unknown
Was infant vitamin B12 levels tested? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was infant vitamin B12 deficient? ☐ Yes ☐ No ☐ Unknown
Was total plasma homocysteine tested? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was total plasma homocysteine: □ Elevated □ Normal □ Unknown

Were enzyme complementation studies completed? ☐ Yes ☐ No ☐ Unknown	[IF YES] Were complementation studies: □ Consistent with disease □ Normal activity (not consistent with disease) □ Unknown
Was mutation analysis done? Yes No Unknown	[IF YES] What genes were included in the mutation analysis? (select all that apply) METHYLMALONYL-CoA MUTASE Other gene:
	Allele 1: ☐ Variant known to be disease causing ☐ Variant of unknown significance ☐ Variant of unknown significance (predicted to be pathogenic) ☐ Wild Type (Normal) ☐ Unknown Allele 2: ☐ Variant known to be disease causing ☐ Variant of unknown significance ☐ Variant of unknown significance (predicted to be pathogenic) ☐ Wild Type (Normal) ☐ Unknown

Methylmalonic Acidemia (cobalamin Final Diagnosis as determined by metabolic ☐ Cobalamin A deficiency (Cbl A) ☐ Cobalamin B deficiency (Cbl B) ☐ Cobalamin Dv2 deficiency (Cbl Dv2) ☐ Maternal vitamin B12 deficiency ☐ Succinate-CoA ligase deficiency ☐ Unclassified ☐ Unknown	disorders; CbI A, CbI B, CbI Dv2) geneticist or clinician performing follow-up:
	Enzymatic
Was serum MMA level tested? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was MMA level in serum: □ Elevated □ Normal □ Unknown
Was urine MMA level tested? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was MMA level in urine: Elevated Normal Unknown
Were plasma acylcarnitines tested? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was C3 level □ Elevated □ Normal □ Unknown
Was maternal vitamin B12 levels tested? ☐ Yes ☐ No ☐ Unknown	[IF YES]Was maternal vitamin B12 deficient?☐ Yes☐ No☐ Unknown
Was infant vitamin B12 levels tested? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was infant vitamin B12 deficient? □ Yes □ No □ Unknown
Was total plasma homocysteine tested? ☐ Yes ☐ No ☐ Unknown	[IF YES]Was total plasma homocysteine:□ Elevated□ Normal□ Unknown

Were enzyme complementation studies completed? ☐ Yes ☐ No ☐ Unknown	 [IF YES] Were complementation studies: □ Consistent with disease □ Normal activity (not consistent with disease) □ Unknown
Molecul	ar Genetics
Was mutation analysis done? ☐ Yes ☐ No ☐ Unknown	 [IF YES] What genes were included in the mutation analysis? (select all that apply) □ MMAA gene □ MMAB gene □ Other gene:
	[For each gene selected] Check the types of variants found on: Allele 1: □ Variant known to be disease causing □ Variant of unknown significance □ Variant of unknown significance (predicted to be pathogenic) □ Wild Type (Normal) □ Unknown Allele 2: □ Variant known to be disease causing □ Variant of unknown significance □ Variant of unknown significance (predicted to be pathogenic) □ Wild Type (Normal) □ Unknown

Methylmalonic Acidemia with Homocystinuria (Cbl C, Cbl D, Cbl F, Cbl Dv1, Cbl J)

*Secondary RUSP Condition

	Cobalamin C deficiency (Cbl C) Cobalamin D deficiency (Cbl D) Cobalamin F deficiency (Cbl F) Cobalamin Dv1 deficiency (Cbl Dv1) Cobalamin J deficiency (Cbl J) Maternal vitamin B12 deficiency Succinate-CoA ligase deficiency Unclassified Other cobalamin deficiency Unknown	icist or clinician performing follow-up:
	Enz	ymatic
Wa	s serum MMA level tested?	[IF YES]
	Yes	Was MMA level in serum:
	No	□ Elevated
	Unknown	□ Normal
		□ Unknown
Wa	s urine MMA level tested?	[IF YES]
	Yes	Was MMA level in urine:
	No	☐ Elevated
	Unknown	□ Normal
		□ Unknown
We	ere plasma acylcarnitines tested?	[IF YES]
	Yes	Was C3 level
	No	
	Unknown	☐ Elevated ☐ Normal
		☐ Unknown
Wa	ns maternal vitamin B12 levels tested?	[IF YES]
	Yes	Was maternal vitamin B12 deficient?
	No	□ Yes
	Unknown	□ No
		☐ Unknown
\A/-	ns infant vitamin B12 levels tested?	[IF YES]
		-
	Yes	Was infant vitamin B12 deficient?
	No	Yes
Ц	Unknown	□ No
		☐ Unknown

Was total plasma homocysteine tested? ☐ Yes ☐ No ☐ Unknown Were enzyme complementation studies completed? ☐ Yes ☐ No ☐ No	<pre>[IF YES] Was total plasma homocysteine: □ Elevated □ Normal □ Unknown [IF YES] Were complementation studies: □ Consistent with disease □ Normal activity (not consistent with disease)</pre>
□ Unknown	□ Unknown
Was mutation analysis done? Yes Unknown	ar Genetics [IF YES] What genes were included in the mutation analysis? (select all that apply) □ MMACHC □ MMADHC □ LMBRD1 □ ABCD4 □ HCFC1 □ C2ORF25 □ Other gene:
	[For each gene selected] Check the types of variants found on: Allele 1: Variant known to be disease causing Variant of unknown significance Variant of unknown significance (predicted to be pathogenic) Wild Type (Normal) Unknown Allele 2: Variant known to be disease causing Variant of unknown significance Variant of unknown significance Variant of unknown significance (predicted to be pathogenic) Wild Type (Normal) Unknown

Fatty Acid Disorders

Primary Carnitine Deficiency/ Carnitine Uptake Deficiency (CUD)

Final Diagnosis as determined by metabolic geneticist or clinician performing follow-up: Carnitine Uptake Deficiency (CUD)		
□ Maternal Carnitine Deficiency (primary and secondary)□ Unknown		
Enzy	/matic	
Was urine carnitine tested? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was fractional excretion of free carnitine level: □ Elevated □ Normal □ Unknown Was 3-methylcrotonyl glycine level □ Elevated □ Normal	
Were plasma carnitine levels tested? ☐ Yes ☐ No ☐ Unknown	☐ Unknown [IF YES] Was free carnitine (CO) ☐ Low ☐ Normal ☐ Unknown	
Were other causes for carnitine loss ruled out? ☐ Yes ☐ No ☐ Unknown		
Was enzyme analysis for carnitine deficiency enzyme activity completed? □ Yes □ No □ Unknown	[IF YES]Was enzyme activity:□ Consistent with disease□ Normal activity (not consistent with disease)□ Unknown	
Molecula	ar Genetics	
Was a mutation analysis done? ☐ Yes ☐ No ☐ Unknown	[IF YES] What genes were included in the mutation analysis? (select all that apply) □ SCL22A5 □ Other gene:	

[For each gene selected]
Check the types of variants found on:
Allele 1: ☐ Variant known to be disease causing ☐ Variant of unknown significance ☐ Variant of unknown significance (predicted to be pathogenic) ☐ Wild Type (Normal) ☐ Unknown
Allele 2: ☐ Variant known to be disease causing ☐ Variant of unknown significance ☐ Variant of unknown significance (predicted to be pathogenic) ☐ Wild Type (Normal) ☐ Unknown

Medium-chain acyl-CoA Dehydrogenase Deficiency (MCAD)

Enz	ymatic
Were urine organic acids or aclyglycines tested?	[IF YES]
Yes	Was Hexanoylglycine level:
□ No	□ Elevated
☐ Unknown	□ Normal
	☐ Unknown
Were plasma acylcarnitines tested?	[IF YES]
☐ Yes	Was C8 level:
□ No	□ Elevated
☐ Unknown	□ Normal
	☐ Unknown
	Was repeat C8 level:
	☐ Elevated
	□ Normal
	☐ Unknown
	Was C8>C10 level:
	□ Yes
	□ No
	☐ Unknown
	Was C8>C6 level:
	□ Yes
	□ No
	☐ Unknown
	Was C6 level:
	☐ Elevated
	□ Normal
	☐ Unknown
	Was C10 level:
	☐ Elevated ☐ Normal
	☐ Unknown

Was functional analysis of fatty acid oxidation in cultured fibroblasts performed? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was functional fibroblast analysis: □ Consistent with disease □ Normal activity (not consistent with disease) □ Unknown
Was enzyme analysis for MCAD enzyme activity completed? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was enzyme activity: □ Consistent with disease □ Normal activity (not consistent with disease) □ Unknown
Molecul	ar Genetics
Was a mutation analysis done? ☐ Yes ☐ No ☐ Unknown	[IF YES] What genes were included in the mutation analysis? (select all that apply) □ ACADM □ Other gene:
	[For each gene selected] Check the types of variants found on: Allele 1: □ Variant known to be disease causing □ Variant of unknown significance □ Variant of unknown significance (predicted to be pathogenic) □ Wild Type (Normal) □ Unknown Allele 2: □ Variant known to be disease causing □ Variant of unknown significance □ Variant of unknown significance (predicted to be pathogenic) □ Wild Type (Normal) □ Unknown

Trifunctional Protein Deficiency (TFP)

Enz	ymatic
Were urine organic acids tested? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was C12-OH dicarboxylic acid level: □ Elevated □ Normal □ Unknown Was C10-OH dicarboxylic acid level: □ Elevated □ Normal □ Unknown
Were plasma acylcarnitines tested? Yes No Unknown	[IF YES] Was C16-OH level: □ Elevated □ Normal □ Unknown Was C16:1-OH level: □ Elevated □ Normal □ Unknown Was C18-OH level: □ Elevated □ Normal □ Unknown Was C18-OH level: □ Elevated □ Normal □ Unknown
	☐ Elevated ☐ Normal ☐ Unknown
Was enzyme analysis for TFP enzyme activity completed? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was enzyme activity: □ Consistent with disease □ Normal activity (not consistent with disease) □ Unknown

Was functional analysis of fatty acid oxidation in cultured fibroblasts performed? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was functional fibroblast analysis: □ Consistent with disease □ Normal activity (not consistent with disease) □ Unknown
Molecul	ar Genetics
Was a mutation analysis done? ☐ Yes ☐ No ☐ Unknown	[IF YES] What genes were included in the mutation analysis? (select all that apply) □ HADHA □ HADHB □ Other gene:
	[For each gene selected] Check the types of variants found on: Allele 1: □ Variant known to be disease causing □ Variant of unknown significance □ Variant of unknown significance (predicted to be pathogenic) □ Wild Type (Normal) □ Unknown Allele 2: □ Variant known to be disease causing □ Variant of unknown significance □ Variant of unknown significance (predicted to be pathogenic) □ Wild Type (Normal) □ Unknown

Long-chain L-3 Hydroxyacyl-CoA Dehydrogenase Deficiency (LCHAD)

Enzymatic		
Were urine organic acids tested? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was C12-OH dicarboxylic acid level: □ Elevated □ Normal □ Unknown Was C10-OH dicarboxylic acid level: □ Elevated □ Normal □ Unknown	
Were plasma acylcarnitines tested? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was C16-OH level:	
Was enzyme analysis for TFP enzyme activity completed? ☐ Yes ☐ No ☐ Unknown	 [IF YES] Was enzyme activity: □ Consistent with disease □ Normal activity (not consistent with disease) □ Unknown 	

Was functional analysis of fatty acid oxidation in cultured fibroblasts performed? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was functional fibroblast analysis: □ Consistent with disease □ Normal activity (not consistent with disease) □ Unknown
Molecul	ar Genetics
Was a mutation analysis done? Yes No Unknown	<pre>[IF YES] What genes were included in the mutation analysis? (select all that apply) □ HADHA □ HADHB □ Other gene: □ [For each gene selected] Check the types of variants found on: Allele 1: □ Variant known to be disease causing □ Variant of unknown significance □ Variant of unknown significance (predicted to be pathogenic) □ Wild Type (Normal) □ Unknown Allele 2: □ Variant known to be disease causing □ Variant of unknown significance □ Variant of unknown significance □ Variant of unknown significance (predicted to be pathogenic) □ Wild Type (Normal) □ Unknown</pre>

Very Long-chain acyl-CoA Dehydrogenase Deficiency (VLCAD)

Enzymatic		
Were plasma acylcarnitines tested?	[IF YES]	
□ Yes	Was C14:1 level:	
□ No	☐ Elevated (on more than one sample)	
☐ Unknown	□ Normal	
	☐ Unknown	
	Was C14:2-OH level:	
	□ Elevated	
	□ Normal	
	☐ Unknown	
	Was C14 level:	
	□ Elevated	
	□ Normal	
	☐ Unknown	
Was enzyme analysis for VLCAD enzyme activity	[IF YES]	
completed?	Was enzyme activity:	
Yes	☐ Consistent with disease	
□ No	Normal activity (not consistent with disease)	
Unknown	☐ Unknown	
Was functional analysis of fatty acid oxidation	[IF YES]	
in cultured fibroblasts performed?	Was functional fibroblast analysis:	
Yes	☐ Consistent with disease	
□ No	☐ Normal activity (not consistent with disease)	
Unknown	☐ Unknown	
Molecular Genetics		
Was a mutation analysis done?	[IF YES]	
☐ Yes	What genes were included in the mutation	
□ No	analysis? (select all that apply)	
☐ Unknown	□ ACADVL	
	Other gene:	

[For each gene selected]
Check the types of variants found on:
Allele 1: ☐ Variant known to be disease causing ☐ Variant of unknown significance ☐ Variant of unknown significance (predicted to be pathogenic) ☐ Wild Type (Normal) ☐ Unknown
Allele 2: ☐ Variant known to be disease causing ☐ Variant of unknown significance ☐ Variant of unknown significance (predicted to be pathogenic) ☐ Wild Type (Normal) ☐ Unknown

Amino Acid Disorders

Argininosuccinic Acidemia/ Aciduria (ASA)

Final diagnosis as determined by a metabolic geneticist or clinician performing following-up: Argininosuccinic Acidemia/ Aciduria (ASA) Pyruvate carboxylase deficiency Unknown			
	Enz	ymatic	
	ere plasma amino acids tested? Yes No Unknown	[IF YES] Was plasma ASA level: □ Elevated □ Normal □ Unknown Was Citrulline level: □ Elevated □ Normal □ Unknown	
Wee	ere plasma urine acids tested? Yes No Unknown	[IF YES] Was urine ASA level? □ Elevated □ Normal □ Unknown Was urine Citrulline level? □ Elevated □ Normal □ Unknown	
cor	is enzyme analysis for ASA enzyme activity npleted? Yes No Unknown	[IF YES] Was enzyme analysis: □ Consistent with disease □ Normal activity (not consistent with disease) □ Unknown	
	Molecular Genetics		

Was a mutation analysis done? ☐ Yes ☐ No ☐ Unknown	[IF YES] What genes were included in the mutation analysis? (select all that apply) □ ASL □ Other gene:
	[For each gene selected] Check the types of variants found on: Allele 1: Variant known to be disease causing Variant of unknown significance Variant of unknown significance (predicted to be pathogenic) Wild Type (Normal) Unknown Allele 2: Variant known to be disease causing Variant of unknown significance Variant of unknown significance Variant of unknown significance (predicted to be pathogenic) Wild Type (Normal) Unknown

Citrullinemia, Type I (CIT)

Final diagnosis as determined by a metabolic geneticist or clinician performing following-up ☐ Citrullinemia, Type I ☐ Pyruvate Carboxylase Deficiency ☐ Unknown			
Enz	ymatic		
Were plasma amino acids tested? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was plasma ASA level: □ Present □ Absent □ Unknown Was Citrulline level: □ Elevated □ Normal □ Unknown		
Was blood ammonia levels tested? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was blood ammonia level: □ Elevated □ Normal □ Unknown		
Was enzyme analysis for Citrullinemia type 1 enzyme activity completed? ☐ Yes ☐ No ☐ Unknown	[IF YES]Was enzyme analysis:□ Consistent with disease□ Normal activity (not consistent with disease)□ Unknown		
Molecular Genetics			
Was a mutation analysis done? ☐ Yes ☐ No ☐ Unknown	[IF YES] What genes were included in the mutation analysis? (select all that apply) □ ASS1 □ Other gene:		

[For each gene selected]
Check the types of variants found on:
Allele 1: ☐ Variant known to be disease causing ☐ Variant of unknown significance ☐ Variant of unknown significance (predicted to be pathogenic) ☐ Wild Type (Normal) ☐ Unknown
Allele 2: ☐ Variant known to be disease causing ☐ Variant of unknown significance ☐ Variant of unknown significance (predicted to be pathogenic) ☐ Wild Type (Normal) ☐ Unknown

Classic Phenylketonuria (PKU) and HyperpFinal diagnosis as determined by a metabolic gene ☐ Classic phenylketonuria (PKU) ☐ Benign hyperphenylalaninemia (H-PHE) ☐ HyperPhe diet controlled ☐ Dihydropterine reductase deficiency (DHPR) ☐ DNAJC12 ☐ Parenteral nutrition ☐ Maternal PKU ☐ Unknown	• • • • •
	ymatic
Were plasma amino acids tested? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was Phe level: □ Elevated (>120umol/L on unrestricted diet) □ Normal □ Unknown Was Phe/Tyr level: □ Elevated □ Normal □ Unknown
Were biopterin studies done? ☐ Yes ☐ No ☐ Unknown	[IF YES] Were biopterin studies: □ Normal □ Abnormal □ Unknown
Was enzyme analysis for Hyperphe (inclusive of classic PKU) enzyme activity completed? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was enzyme analysis: □ Consistent with disease □ Normal activity (not consistent with disease) □ Unknown
Molecul	ar Genetics
Was a mutation analysis done? ☐ Yes ☐ No ☐ Unknown	[IF YES] What genes were included in the mutation analysis? (select all that apply) □ PAH □ Other gene:

[For each gene selected] Check the types of variants found on:
Allele 1: □ Variant known to be disease causing □ Variant of unknown significance □ Variant of unknown significance (predicted to be pathogenic) □ Wild Type (Normal) □ Unknown
Allele 2: ☐ Variant known to be disease causing ☐ Variant of unknown significance ☐ Variant of unknown significance (predicted to be pathogenic) ☐ Wild Type (Normal) ☐ Unknown

Homocystinuria (Cystathionine Beta-Synthase (CBS) Deficiency; HCY) Final diagnosis as determined by a metabolic geneticist or clinician performing following-up:

☐ Classic Homocystinuria ☐ Methionine Adenosyltransferase (MAT I/III I ☐ Glycine n-methyltransferase (GNMT) ☐ Adenosylhomocysteine Hydrolase Deficienc ☐ Unknown		
Enz	ymatic	
Were plasma amino acids tested? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was Methionine level: □ Elevated □ Normal □ Unknown	
Was plasma Homocysteine tested? ☐ Yes ☐ No ☐ Unknown	[IF YES]Was plasma Homocysteine level:☐ Elevated☐ Normal☐ Unknown	
Was enzyme analysis for CBS enzyme activity completed? ☐ Yes ☐ No ☐ Unknown	[IF YES]Was enzyme analysis:□ Consistent with disease□ Normal activity (not consistent with disease)□ Unknown	
Molecular Genetics		
Was a mutation analysis done? ☐ Yes ☐ No ☐ Unknown	[IF YES]What genes were included in the mutation analysis? (select all that apply)□ CBS□ Other gene:	

[For each gene selected]
Check the types of variants found on:
Allele 1: ☐ Variant known to be disease causing ☐ Variant of unknown significance ☐ Variant of unknown significance (predicted to be pathogenic) ☐ Wild Type (Normal) ☐ Unknown
Allele 2: ☐ Variant known to be disease causing ☐ Variant of unknown significance ☐ Variant of unknown significance (predicted to be pathogenic) ☐ Wild Type (Normal) ☐ Unknown

Maple Syrup Urine Disease (MSUD) Final diagnosis as determined by a metabolic geneticist or clinician performing following-up: ☐ Classic □ Intermediate ☐ Thiamine-response ☐ Hydroxyprolinemia □ Unclassified ☐ Unknown **Enzymatic** Were plasma amino acids tested? [IF YES] ☐ Yes Was Alloisoleucine level: □ No ☐ Elevated ☐ Unknown □ Normal ☐ Unknown Was Leucine level: ☐ Elevated □ Normal ☐ Unknown Was Isoleucine level: □ Elevated □ Normal ☐ Unknown Was Valine level: ☐ Elevated □ Normal ☐ Unknown Was Leu>Val level: ☐ Yes □ No ☐ Unknown

Were urine organic acids tested? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was 2-ketoisocaproic acid level: □ Elevated □ Normal □ Unknown
	Was 2-OH Isovaleric acid level: ☐ Elevated ☐ Normal ☐ Unknown
	Was 2-ketomethyl valeric acid level ☐ Elevated ☐ Normal ☐ Unknown
Was enzyme analysis for MSUD enzyme activity completed? ☐ Yes	[IF YES]Was enzyme analysis:□ Consistent with disease
□ No □ Unknown	□ Normal activity (not consistent with disease)□ Unknown
Molecul	ar Genetics
Was a mutation analysis done? ☐ Yes ☐ No ☐ Unknown	[IF YES] What genes were included in the mutation analysis? (select all that apply)
	□ DBT □ BCKDHB □ DLD □ BCKDHA □ Other gene:

[For each gene selected] Check the types of variants found on:
Allele 1: □ Variant known to be disease causing □ Variant of unknown significance □ Variant of unknown significance (predicted to be pathogenic) □ Wild Type (Normal) □ Unknown
 Allele 2: □ Variant known to be disease causing □ Variant of unknown significance □ Variant of unknown significance (predicted to be pathogenic) □ Wild Type (Normal) □ Unknown

Tyrosinemia Type I (TYR-1)

Final diagnosis as determined by a metabolic gen	eticist or clinician performing following-up:		
☐ Tyrosinemia, Type I (hepatorenal)			
☐ Transient Tyrosinemia of the neonate (TTN)			
☐ Unknown			
Enz	ymatic		
Were plasma organic acids tested?	[IF YES]		
☐ Yes			
□ No	Was plasma succinylacetone level:		
□ Unknown	□ Elevated		
	□ Normal		
	□ Unknown		
	Was plasma tyrosine level:		
	□ Elevated		
	□ Normal		
	☐ Unknown		
	for versi		
Were urine organic acids tested?	[IF YES]		
Yes			
□ No	Was urine succinylacetone level:		
□ Unknown	☐ Elevated		
	□ Normal		
	☐ Unknown		
	Was urine tyrosine level:		
	☐ Elevated		
	□ Normal		
	☐ Unknown		
NA/ac a company a conclusion for a formation and a contract and a			
Was enzyme analysis for fumarylacetoacetate hydrolase completed?	[IF YES]		
yes	Was enzyme analysis:		
□ No	Consistent with disease		
	Normal activity (not consistent with disease)		
Unknown	☐ Unknown		
Molecul	ar Genetics		

Was a mutation analysis done? ☐ Yes ☐ No ☐ Unknown	[IF YES] What genes were included in the mutation analysis? (select all that apply) □ FAH □ Other gene:
	[For each gene selected] Check the types of variants found on: Allele 1: □ Variant known to be disease causing □ Variant of unknown significance □ Variant of unknown significance (predicted to be pathogenic) □ Wild Type (Normal) □ Unknown Allele 2: □ Variant known to be disease causing □ Variant of unknown significance □ Variant of unknown significance (predicted to be pathogenic) □ Wild Type (Normal) □ Unknown

Endocrine Disorders

Congenital Hypothyroidism (CH)

	Secondary Congenital Hypothyroidism TBG Deficiency (Thyroxine Binding Globulin) or other protein binding defect	
	Unknown	
	Enz	ymatic
Wa	s Serum TSH tested? Yes No Unknown	[IF YES] What was the level: □ TSH > 10 mU/L □ TSH 6-10 mU/L □ TSH <10 mU/L □ TSH <6 mU/L □ Unknown Was it tested before initiation of treatment? □ Yes □ No □ Unknown
Wa	s Serum Total T4 tested? Yes No Unknown	<pre>[IF YES] Was Serum Total T4 below the age-established reference range? □ Yes □ No □ Unknown Was it tested before initiation of treatment? □ Yes □ No □ Unknown</pre>

Was Serum Free T4 tested? ☐ Yes ☐ No ☐ Unknown	<pre>[IF YES] Was Serum Free T4 below the age-established reference range? □ Yes □ No □ Unknown Was it tested before initiation of treatment? □ Yes □ No □ Unknown</pre>
Does this baby have other pituitary hormone deficiencies? Yes No Unknown	
Does this baby have midline defects? ☐ Yes ☐ No ☐ Unknown	
Was TBG tested? ☐ Yes ☐ No ☐ Unknown	[IF YES] Was TBG below the age established reference range? ☐ Yes ☐ No ☐ Unknown
Was T3 or T4 resin uptake tested? ☐ Yes ☐ No ☐ Unknown	 [IF YES] Was T3 or T4 resin uptake above the ageestablished reference range? ☐ Yes ☐ No ☐ Unknown

Congenital Adrenal Hyperplasia (CAH)

Final Diagnosis as determined by clinician perform	Final Diagnosis as determined by clinician performing follow-up:		
\square Classic 21-Hydroxylase Deficiency-Salt Wasting	•		
☐ Classic 21-Hydroxylase Deficiency-Simple Virili	zing		
☐ Other Adrenal disorder: other final diagnosis r	iame		
☐ Unknown			
Enz	ymatic		
Societal Sex ☐ Male ☐ Female ☐ Unknown ☐ Unspecified			
•	(ir.vec)		
Was confirmatory serum 17-OHP level obtained? ☐ Yes ☐ No ☐ Unknown	<pre>[IF YES] Was there a value at baseline: □ >10,000 ng/dl □ 1000-10,000 ng/dl; □ <1000 ng/dl; □ Unknown Was it tested before initiation of treatment? □ Yes □ No Was there a result after ACTH stimulation: □ >10,000 ng/dl □ 1000-10,000 ng/dl; □ <1000 ng/dl; □ Unknown Was it tested before initiation of treatment? □ Yes</pre>		
Was tandem mass spectrometry urinary steroid profile obtained? ☐ Yes ☐ No ☐ Unknown	☐ No [IF YES] Were the urinary spectrometry steroid profile results: ☐ Indicative of 21-Hydroxylase Deficiency CAH ☐ Unknown		

Was serum sodium level measured before	[IF YES]
initiation of treatment? ☐ Yes	Was the sodium level:
□ No	□ <135 mEq/L
☐ Unknown	□ > 135 mEq/L
	☐ Unknown
Mac places renip activity level	[IF YES]
Was plasma renin activity level measured at time of initiation of	•
	Was plasma renin activity normal for age?
□ Yes	□ Yes
□ No	□ No
☐ Unknown	☐ Unknown
	Was it tested before initiation of treatment?
	☐ Yes
	□ No
Clinica	l Results
Is there evidence of salt wasting (e.g., shock or severe failure to thrive)? Yes No Unknown	
	[IF YES]
Is there supportive clinical or laboratory evidence of CAH?	Is the evidence (check all that apply):
☐ Yes	☐ Ambiguous genitalia, with 46 XX karyotype
□ No	☐ Normal genitalia, with 46 XY karyotype
☐ Unknown	☐ Other hormonal evidence of CAH
Molecul	ar Genetics
Was mutation analysis done?	[IF YES]
□ Yes	Mhat ganas ware included in the moutation analysis
LI NO	What genes were included in the mutation analysis? (select all that apply)
☐ Unknown	(Sciect all that apply)
	□ CYP21A2
	☐ Other gene:

[For each gene selected]
Check the types of variants found on:
Allele 1 ☐ Variant known to be disease causing ☐ Variant of unknown significance ☐ Variant of unknown significance (predicted to be pathogenic) ☐ Wild Type (Normal) ☐ Unknown
Allele 2 ☐ Variant known to be disease causing ☐ Variant of unknown significance ☐ Variant of unknown significance (predicted to be pathogenic) ☐ Wild Type (Normal)
☐ Unknown

Hemoglobinopathies

Presence of Hb S

	nal diagnosis as determined by a clinician performation of S, Beta 0-thalassemia – HB S/B0Th S,S Disease (Sickle Cell Anemia) – HbSS S, Beta + Thalassemia – HbS/B + Th S,C Disease – Hb S/C S, Other; other result name	form	ning the follow-up:
	Unknown		
\A/-	Diagnos		·
	s qualitative (IEF or HPLC) testing completed? Yes No	-	YES] at were the results? FS
	Unknown		FSC FSA FSA ₂ FSAA ₂ Other; other result name Unknown
	s quantitative (HPLC or electrophoresis) ting completed?	[IF \	YES]
	Yes	Wh	at were the results?
	No		FS
	Unknown		FSC
			FS with high A_2
			FSA with high A_2
			FSA
			Other; other result name
			Unknown

Was mutation analysis performed?	[IF YES]
□ Yes	Check the type of variant found on:
□ No	
☐ Unknown	Allele 1 □ S □ C □ Beta + Thal □ Other; □ Unknown Allele 2 □ S □ C □ Beta + Thal □ Beta ⁰ + Thal □ Other; □ Unknown
NBS result	[IF YES]
☐ Yes	[, 125]
□ No	What were the results?
☐ Unknown	□ FS
	□ FSC
	□ FSA
	□ FSA ₂
	□ Other
	☐ Unknown
Was a CBC performed?	[IF YES]
Yes	What were the results?
□ No	□ Normal – high MCV
☐ Unknown	□ Low MCV
	□ Unknown

Were family studies (in parents) done?	[IF YES]
☐ Yes	Maternal Status: what were the results?
□ No	☐ Carrier S
☐ Unknown	☐ Carrier C
	☐ Carrier Beta + Thal
	☐ Carrier Beta ⁰ Thal
	Other:
	☐ Unknown
	- Officiowii
	Paternal Status: what were the results?
	☐ Carrier S
	☐ Carrier <i>C</i>
	☐ Carrier Beta + Thal
	☐ Carrier <i>Beta⁰ Thal</i>
	□ Other:
	☐ Unknown
Was there a positive family history?	
☐ Yes	
□ No	
☐ Unknown	
Were HPLC & IEF tested on the same sample	[IF YES]
from the infant?	[
Yes	What were the results?
□ No	□ FS
☐ Unknown	□ FSC
	□ FSA ₂
	☐ FSAA₂
	□ Other
	□ Unknown
	5:
Were Hgb tests (electrophoresis or HPLC)	[IF YES]
performed on family members?	What were the results?
Yes	Positive
□ No	Negative
☐ Unknown	☐ Unknown

Presence of Other Hb Variant

*This is a Secondary RUSP Condition

Final diagnosis as determined by a clinician perfor Hemoglobin C Disease Hemoglobin D Disease Hemoglobin E Disease Hemoglobin O-Arab Disease Other Hemoglobin Disease; please describ	
-	tic Workup
Alpha thalassemia present? ☐ Yes ☐ No ☐ Unknown	
Was qualitative (IEF or HPLC) testing completed?	[IF YES]
Yes	What were the results?
□ No	□ FC
Unknown	□ FD □ FE
	□ FO _{ARAB}
	☐ Other; other result name
	□ Unknown
Was quantitative (HPLC or electrophoresis)	[IF YES]
testing completed?	What were the results?
Yes	□ FC
□ No	□ FD
Unknown	☐ FE ☐ FO _{ARAB}
	Other; other result name
	Unknown
	1

Was mutation analysis performed?	[IF YES]
□ Yes	Check the type of variant found on allele 1:
□ No	□ <i>C</i>
☐ Unknown	\Box D
	□ <i>E</i>
	□ O _{ARAB}
	☐ Other; other name
	□ Unknown
	Check the type of variant found on allele 2:
	□ <i>c</i>
	\Box D
	□ <i>E</i>
	□ O _{ARAB}
	□ Beta + Thal
	\square Beta ⁰ + Thal
	Other; other name
	☐ Unknown
NBS result	[IF YES]
□ Yes	What were the results?
□ No	□ FC
☐ Unknown	□ FD
	□ FE
	☐ FO _{ARAB}
	Other; other result name
	Unknown
Was a CBC performed?	[IF YES]
Yes	What were the results?
□ No	□ Normal – high MCV
☐ Unknown	□ Low MCV

Were family studies (in parents) done?	Maternal Status: what were the results?
□ Yes	☐ Carrier <i>C</i>
□ No	☐ Carrier D
☐ Unknown	□ Carrier E
	☐ Carrier O _{Arab}
	☐ Carrier Beta + Thal
	☐ Carrier <i>Beta⁰ Thal</i>
	Other:
	☐ Unknown
	- Chikhowh
	Paternal Status: what were the results?
	□ Carrier C
	□ Carrier D
	□ Carrier E
	☐ Carrier O _{Arab}
	☐ Carrier Beta + Thal
	☐ Carrier Beta® Thal
	☐ Other:
	☐ Unknown
	- Chichewh
Was there a positive family history?	
□ Yes	
□ No	
□ Unknown	
Were Hgb tests (electrophoresis or HPLC)	[IF YES]
performed on family members?	What were the results?
☐ Yes	□ Positive
□ No	□ Negative
☐ Unknown	☐ Unknown

Lysosomal Storage Disorders

Note: Case Confirmatory Diagnosis Follow-up for Mucopolysaccharidosis Type II (MPS II) is in development

Mucopolysaccharidosis Type I (MPS I)

Fina	al Diagnosis as determined by metabolic geneti	cist or clinician performing follow-up:
	MPS I—Severe	
	MPS I—Severity not determined	
	MPS I—attenuated	
	Uncertain Type/Onset	
	Unknown	
Enzymatic		
Wa	s enzyme activity tested?	[IF YES]
☐ Yes ☐ No ☐ Unknown	What was the enzyme level?	
	☐ Within lab known affected range	
		□ Normal
		□ Unknown
We	ere urine GAGS tested?	[IF YES]
	Yes	What was the urine GAG level?
□ No □ Unknown	□ Elevated	
	□ Normal	
		☐ Unknown

Clinical symptoms/lab findings? ☐ Symptoms present and documented by specialists. Public health (PH) program continued to collect data through the development of symptoms ☐ No symptoms by the time the PH Program closes follow-up (either due to child being lost to follow-up OR program policy on follow-up time ☐ Unknown	Clinical symptoms consistent with MPS-I include: Hepatosplenomegaly, Coarse facial features, Hydrocephalus, Skeletal deformities (dysostosis multiplex), Corneal clouding, Large tongue, Prominent forehead, Joint stiffness, Short stature, frequent ear infections and hearing loss, hernia	
Molecular Genetics		
Were variants detected in genes known	[IF YES]	

Molecular Genetics		
Were variants detected in genes known	[IF YES]	
to be associated with MPS I?	Check the types of variants found on:	
□ Yes		
□ No	Allele 1:	
□ Unknown	☐ Pathogenic variant and associated with SEVERE disease	
	☐ Pathogenic or likely pathogenic variant	
	☐ Variant of unknown significance	
	☐ Variant known to be associated with	
	ATTENUATED disease.	
	☐ Wild Type (Normal) ☐ Unknown	
	- Olikilowii	
	Allele 2:	
	☐ Pathogenic variant and associated with SEVERE disease	
	☐ Pathogenic or likely pathogenic variant	
	☐ Variant of unknown significance	
	☐ Variant known to be associated with	
	ATTENUATED disease.	
	☐ Wild Type (Normal)	
	□ Unknown	

Pompe Disease

Final Diagnosis as determined by metabolic geneti ☐ Infantile Onset (IO) Pompe Disease ☐ Late Onset (LO) Pompe Disease ☐ Uncertain Type/Onset ☐ Unknown	cist or clinician performing follow-up:
Enz	ymatic
Was enzyme activity tested in blood (not DBS sample)? Yes No Unknown	 [IF YES] What was the enzyme level? □ Within lab known affected range for infantile onset (IO) □ Low (above affected range, for IO, may or may not be in late-onset (LO range), but should not be above LO range)) □ Within lab known affected range for late onset (LO) □ Low (above affected range, for LO not normal) □ Unknown
Was enzyme activity tested in skin/muscle? ☐ Yes ☐ No ☐ Unknown	[IF YES] What was the enzyme activity? □ Positive skin or muscle biopsy □ Unknown
Pompe? Yes No Unknown	 [IF YES] Findings: □ Positive findings on chest X-ray/EKG/ECHO in newborn period □ Positive findings on chest X-ray/EKG/ECHO
Lab findings for CK/AST/ALT/LDH/Urine Hex4? ☐ Elevated ☐ Not Present ☐ Unknown ☐ Untested	

☐ Symptoms present after one year of age and documented by specialists. PH program	Clinical symptoms consistent with Pompe Disease: progressive muscle weakness, need for respiratory assistance, swaying gait or waddle, Lordosis, kyphosis, or scoliosis		
Molecular Genetics			

Were variants detected in genes known		[IF YES]		
to I	be associated with Pompe Disease?	Check the types of variants found on:		
	Yes			
	No	Allele 1:		
	Unknown	☐ Pathogenic		
			Pathogenic variant and associated with	
			infantile onset	
			Novel variant that is likely pathogenic	
			Pathogenic variant or likely pathogenic variant, with deletion or duplication consistent with infantile onset	
			Pathogenic and associated with non-classical	
			disease, or variant of uncertain significance	
			Pathogenic or likely pathogenic variant, no other variants found; duplication/deletion	
			testing not done or not known	
			Pathogenic or likely pathogenic variant; no	
			other variants found	
			Wild Type (Normal)	
			Unknown	
		Alle	ele 2:	
			Pathogenic	
			Pathogenic variant and associated with	
			infantile onset	
			Novel variant that is likely pathogenic	
			Pathogenic variant or likely pathogenic variant,	
			with deletion or duplication consistent with	
			infantile onset	
			Pathogenic and associated with non-classical disease, or variant of uncertain significance	
			Pathogenic or likely pathogenic variant, no	
			other variants found; duplication/deletion	
			testing not done or not known	
			Pathogenic or likely pathogenic variant; no	
			other variants found	
			Wild Type (Normal)	
			Unknown	
		<u> </u>		

Other Disorders

Biotinidase Deficiency (BIOT)

Final Diagnosis as determined by metabolic geneticist or clinician performing follow-up: ☐ Profound Biotinidase deficiency ☐ Partial Biotinidase deficiency		
Unknown		
	Enzymatic [IF YES]	
Was enzyme analysis for biotinidase enzyme activity completed? ☐ Yes	Was enzyme activity:	
□ No □ Unknown	□ 10-30% □ Normal	
	□ Unknown	
Mole	cular Genetics	
Was a mutation analysis performed for biotinidase deficiency? Yes No Unknown	[IF YES] What genes were included in the mutation analysis? (select all that apply)□ BTD□ Other gene:	
	<pre>[For all genes selected] Check the types of variants found on: Allele 1:</pre>	

Galactosemia (GALT)

Final diagnosis as determined by a metabolic geneticist or clinician performing following-up:			
☐ Classic Galactosemia			
☐ Duarte variant galactosemia			
□ Unknown			
Enz	ymatic		
Were GALT levels tested?	[IF YES]		
□ Yes	Was GALT level:		
□ No	□ <10%		
Unknown	□ 10-30%		
	□ Normal		
	□ Unknown		
Was Gal-1-P tested?	[IF YES]		
Yes	Was Gal-1-P level:		
□ No	□ Elevated		
□ Unknown	□ Normal		
	□ Unknown		
Was Urine Galactitol tested?	[IF YES]		
□ Yes	Was Urine Galactitol level:		
□ No	□ Elevated		
☐ Unknown	□ Normal		
	☐ Unknown		
If Variant Galactosemia, was protein	[IF YES]		
phenotyping completed?	Did result indicate:		
□ Yes	☐ Phenotype consistent with variant		
□ No	☐ Phenotype NOT consistent with variant		
Unknown	☐ Unknown		
□ Not applicable			
If Arginase Deficiency, were enzyme studies	[IF YES]		
completed?	Was enzyme activity:		
□ Yes	☐ Consistent with disease		
□ No	☐ Normal activity (not consistent with disease)		
Unknown	☐ Unknown		
□ Not applicable			
Molecular Genetics			

Was a mutation analysis done?	[IF YES]	
☐ Yes	What genes were included in the mutation analysis?	
□ No	(select all that apply)	
☐ Unknown	☐ Galactosemia	
	☐ Other gene:	
	[For each gene selected]	
	Check the types of variants found on:	
	Allele 1 ☐ Variant known to be disease causing ☐ Variant of unknown significance ☐ Variant of unknown significance (predicted to be pathogenic) ☐ Wild Type (Normal) ☐ Unknown	
	Allele 2	
	☐ Variant known to be disease causing	
	☐ Variant of unknown significance	
	☐ Variant of unknown significance (predicted to	
	be pathogenic)	
	☐ Wild Type (Normal)	
	☐ Unknown	

Cystic Fibrosis

Final diagnosis as determined by a metabolic gen CFTR-Related Metabolic Syndrome (CRMS) CFTR-Related Disease Typical Cystic Fibrosis (CF)	eticist or clinician performing following-up:
Unknown	tic Morkup
Diagnos Did the NBS result indicate an elevated IRT? Yes No Unknown	tic Workup
were CFTR mutations detected on the newborn screening mutation panel? ☐ Yes ☐ No ☐ Unknown Mutations seen in patients with CF have been classified as disease-causing, neutral, or varying clinical consequences through the CFTR2 project: http://cftr2.org/browse.php. Additional information about the mutation and the association with lower sweat chlorides can also be found at CFTR2.	Check the type of variant found on allele 1: □ Variant known to be disease causing in CFTR2 □ Variant known to be disease causing in CFTR2 (shown to be associated with lower sweat chlorides) □ Neutral variant □ Variant of varying clinical consequence in CFTR2 □ Wild Type (Normal) □ Unknown (not reported in CFTR2) Check the type of variant found on allele 1: □ Varian known to be disease causing in CFTR2 □ Variant known to be disease causing in CFTR2 (shown to be associated with lower sweat chlorides) □ Neutral variant □ Variant of varying clinical consequence in CFTR2 □ Wild Type (Normal) □ Unknown (not reported in CFTR2)
Did the child have meconium ileus? ☐ Yes ☐ No ☐ Unknown	

W	(IF VEC)		
Was a valid sweat chloride result available?	[IF YES]		
Yes			
□ No □ Unknown	What were the sweat test results (please report on the highest sweat chloride value from one sweat test)?		
	 ≥60 mmol/L (regardless of age) <30 mmol/L (if age <6 months) 30-59 mmol/L (if age < 6 months) <40mmol/L (if age ≥6 months) 40-59 mmol/L (if age ≥6 months) Quantity not Sufficient 		
	[IF NO]		
	If a valid sweat test was not available, were there attempts to obtain a sweat chloride that were quantity not sufficient (QNS)?		
	☐ Yes ☐ No ☐ Unknown		
Was a sweat chloride repeated on a separate	[IF YES]		
	What were the repeat sweat test results (please		
should NOT be reported here)	report on the highest sweat chloride value from		
□ Yes	one sweat test)?		
□ No □ Unknown	 ≥60 mmol/L (regardless of age) <30 mmol/L (if age <6 months) 30-59 mmol/L (if age < 6 months) <40mmol/L (if age ≥6 months) 40-59 mmol/L (if age ≥6 months) Quantity not sufficient (QNS) 		

Was a CFTR mutation panel completed after the	[IF YES]		
newborn screening mutation panel?			
☐ Yes ☐ No ☐ Unknown Mutations seen in patients with CF have been classified as disease-causing, neutral, or varying clinical consequences through the CFTR2 project: http://cftr2.org/browse.php . Additional information about the mutation and the association with lower sweat chlorides can also be found at CFTR2.	Check the type of variant found on allele 1: □ Variant known to be disease causing in CFTR2 □ Variant known to be disease causing in CFTR2 (shown to be associated with lower sweat chlorides) □ Neutral variant □ Variant of varying clinical consequence in CFTR2 □ Wild Type (Normal) □ Unknown (not reported in CFTR2)		
sweat emonaes can also be jound at Er M2.	Check the type of variant found on allele 2: ☐ Variant known to be disease causing in CFTR2 ☐ Variant known to be disease causing in CFTR2 (shown to be associated with lower sweat chlorides) ☐ Neutral variant ☐ Variant of varying clinical consequence in CFTR2 ☐ Wild Type (Normal) ☐ Unknown (not reported in CFTR2)		
If the child was diagnosed after the newborn	[IF PRESENT]		
period, were clinical symptoms associated with CFTR Related Disease present? Select NA if the child was diagnosed during the newborn period. □ Present □ Not Present □ Unknown □ Not applicable	Select all symptoms included: CBAVD Recurrent pancreatitis Nasal polyposis Infertility Focal biliary cirrhosis with portal hypertension		

Summary of common variants as reported on CFTR2 (this is not an exhaustive list; please visit www.CFTR2.org for the latest updated list).

Variant name - HGVS nomenclature	Protein name	Variant legacy name	On ACMG Screening Panel	CFTR2 final call	Associated with lower sweat chloride
c.3717+12191C>T	p.Phe316LeufsX12	1078delT	No	CF-causing	NO
c.579+3A>G	p.Phe342HisfsX28	1154insTC	No	CF-causing	NO
c.3454G>C	No protein name	1717-1G->A	Yes	CF-causing	NO
c.3208C>T	No protein name	1811+1.6kbA->G	No	CF-causing	NO
c.3154T>G	No protein name	1898+1G->A	Yes	CF-causing	NO
c.1585-1G>A	p.Leu671X	2143delT	No	CF-causing	NO
c.1680-1G>A	p.Lys684SerfsX38	2183AA->G	No	CF-causing	NO
c.1766+1G>A	p.Lys684AsnfsX38	2184delA	Yes	CF-causing	NO
c.2490+1G>A	p.Gln685ThrfsX4	2184insA	No	CF-causing	NO
c.2988+1G>A	p.Glu726ArgfsX4	2307insA	No	CF-causing	NO
c.1736A>G	No protein name	2789+5G->A	Yes	CF-causing	NO
c.1408A>G	No protein name	3120+1G->A	Yes	CF-causing	NO
c.1841A>G	No protein name	3120G->A	No	CF-causing	NO
c.2991G>C	No protein name	3272-26A->G	No	CF-causing	NO
c.489+1G>T	p.Lys1177SerfsX15	3659delC	Yes	CF-causing	NO
c.350G>A	No protein name	3849+10kbC->T	Yes	CF-causing	NO
c.4242+1G>T	p.Leu1258PhefsX7	3905insT	No	CF-causing	NO
c.3718-1G>A	p.Leu88llefsX22	394delTT	No	CF-causing	NO
c.1240C>T	No protein name	5T	No	Indeterminat e	YES
c.2260G>A	No protein name	621+1G->T	Yes	CF-causing	NO
c.1727G>C	No protein name	711+1G->T	Yes	CF-causing	NO
c.220C>T	No protein name	711+5G->A	No	CF-causing	NO
c.2834C>T	p.Ala455Glu	A455E	Yes	CF-causing	NO
c.1675G>A	p.Ala559Thr	A559T	No	CF-causing	NO
c.1127_1128insA	p.Ser18ArgfsX16	CFTRdele2,3	No	CF-causing	NO
c.1202G>A or c.1203G>A	p.Asp1152His	D1152H	No	Indeterminat e	YES
c.1923_1931del9insA	p.Glu60X	E60X	No	CF-causing	NO
c.1679G>C	p.Phe508del	F508del	Yes	CF-causing	NO
c.3160C>G	p.Gly1244Glu	G1244E	No	CF-causing	NO
c.4046G>A	p.Gly178Glu	G178R	No	CF-causing	NO
c.4196_4197delTC	p.Gly542X	G542X	Yes	CF-causing	NO
c.3731G>A	p.Gly551Asp	G551D	Yes	CF-causing	NO
c.3197G>A	p.Gly85Glu	G85E	Yes	CF-causing	NO
c.2657+2_2657+3insA	p.lle1027Thr	I1027T	No	Not CF- causing	NO
c.1673T>C	p.lle148Thr	I148T	No	Not CF- causing	NO

c.3763T>C	p.lle336Lys	1336K	No	CF-causing	NO
c.1558G>T	p.lle507del	I507del	Yes	CF-causing	NO
c.3230T>C	p.Leu1077Pro	L1077P	No	CF-causing	NO
c.1040G>A	p.Leu206Trp	L206W	No	CF-causing	NO
c.3302T>A	p.Met1101Lys	M1101K	No	CF-causing	NO
c.274G>A	p.Asn1303Lys	N1303K	Yes	CF-causing	NO
c.617T>G	p.Pro67Leu	P67L	No	CF-causing	NO
c.2764_2765insAG	p.Gln220X	Q220X	No	CF-causing	NO
c.1973_1985del13insAGAA A	p.Gln493X	Q493X	No	CF-causing	NO
c.3196C>T	p.Arg1066Cys	R1066C	No	CF-causing	NO
c.4296_4297insGA	p.Arg1158X	R1158X	No	CF-causing	NO
c.1692delA	p.Arg1162X	R1162X	Yes	CF-causing	NO
c.1055G>A	p.Arg117Cys	R117C	No	CF-causing	NO
c.1466C>A	p.Arg117His	R117H	Yes	Indeterminat e	YES
c.1013C>T	p.Arg334Trp	R334W	Yes	CF-causing	NO
c.532G>A	p.Arg347His	R347H	Yes	CF-causing	NO
c.1040G>C	p.Arg347Pro	R347P	No	CF-causing	NO
c.2908G>C	p.Arg352Gln	R352Q	No	CF-causing	NO
c.2424_2425insAT	p.Arg553X	R553X	Yes	CF-causing	NO
c.2780T>C	p.Arg560Thr	R560T	Yes	CF-causing	NO
c.349C>T	p.Ser1251Asn	S1251N	No	CF-causing	NO
c.1000C>T	p.Ser549Asn	S549N	No	CF-causing	NO
c.3752G>A	p.Ser945Leu	S945L	No	CF-causing	NO
c.1645A>C or c.1647T>G	p.Val520Phe	V520F	No	CF-causing	NO
c.274G>T	p.Trp1282X	W1282X	Yes	CF-causing	NO
c.2128A>T	p.Tyr1092X	Y1092X	No	CF-causing	NO
c.2195T>G	p.Tyr122X	Y122X	No	CF-causing	NO

Severe Combined Immunodeficiencies (SCID)

Final diagnosis as determined by a metabolic geneticist or clinician performing follow-up: □ Classic SCID			
☐ Leaky SCID			
☐ Omenn Syndrome			
☐ Unknown			
Diagnos	tic Workup		
Was the CD3 T cell level tested? [IF YES]			
□ Yes	What was the CD3 T cell level?		
□ No	<300 autologous T cells, undetectable or very		
□ Unknown	few naïve T cells		
	□ 300-1500, few naïve T cells, oligoclonal T cells,		
	or poor T cell diversity		
	□ >80% CD45RO+ □ Any number (not zero)		
	☐ Untested/Unknown		
	D Ontested/Onknown		
Was proliferation to PHA test done?	[IF YES]		
□ Yes	Proliferation to PHA:		
□ No	□ <10% of normal		
□ Unknown	□ 10-50% of normal PHA		
- Olikilowii	☐ 10-30% of Hormal TTIA ☐ 10-30% normal PHA or Absent to Candida/TT		
	□ <30% of normal		
	☐ Any/Unknown		
Was maternal engraftment documented?			
□ Yes			
□ No			
□ Unknown			
Molecular Genetics			

Was mutation analysis done?	[IF YES]
-	Were variants detected in the genes known to be
☐ Yes	associated with SCID?
□ No □ Unknown	□ Yes
L Olknown	□ No
	☐ Unknown
	[IF YES]
	Check the type of variant found on allele 1:
	☐ Pathogenic variant in a known SCID gene
	☐ Pathogenic variant in a known SCID gene on X
	chromosome in a male
	☐ Pathogenic variant in a known SCID gene
	known to be associated with leaky SCID
	(previously reported or in a gene previously associated with combined immunodeficiency)
	☐ Wild Type (Normal)
	☐ Untested/Unknown
	Check the type of variant found on allele 2:
	☐ Pathogenic variant in a known SCID gene
	☐ Pathogenic variant in a known SCID gene
	known to be associated with leaky SCID
	(previously reported or in a gene previously
	associated with immunodeficiency)
	☐ Wild Type (Normal)
	☐ Untested/Unknown
	[IF variants detected=YES]
	Was 22q1 deletion assessed?
	☐ Yes ☐ No
	☐ Unknown
	[IF variants detected=YES]
	Were homozygous or compound heterozygous
	FOXN1 mutations assessed?
	□ Yes
	□ No
	☐ Unknown

[IF variants detected=YES] Were heterozygous TBX1 variants assessed?
□ Yes □ No □ Unknown

Critical Congenital Heart Disease (CCHD) What was the final diagnosis? ☐ CCHD ■ Non-critical CCHD ☐ Other ☐ Unknown **Diagnostic Workup** [IF CCHD SELECTED] □ Truncus Arteriosus ☐ Total Anomalous Pulmonary Venous Connection ☐ Tetralogy of fallot ☐ Pulmonary Atresia ☐ Ebstein's Anomaly ☐ Hypoplastic Left Heart Syndrome ☐ Single ventricle ☐ Tricuspid atresia ☐ Transposition of the great arteries ☐ Double outlet right ventricle □ Coarctation of aorta ☐ Interrupted arch Aortic valve disease If Other selected; please specify_____ Please answer the If Yes, what were the results of the postnatal echocardiogram? following: (select all that apply) **Truncus Arteriosus** Was a Postnatal **Echocardiogram** ☐ Truncus arteriosus Completed? ☐ Truncus arteriosus + Interrupted aortic arch ☐ Yes **Total Anomalous Pulmonary Venous Connection (TAPVC)** □ No ☐ Unknown ☐ Type1 (supracardiac) ☐ Type 2 (cardiac) ☐ Type 3 (infracardiac)

☐ Type 4 (mixed)

	Tetralogy of Fallot (TOF)
	 □ TOF □ TOF, Pulmonary stenosis □ TOF, AVCanal (AVSD) □ TOF, Absent pulmonary valve
	Pulmonary Artesia ☐ Pulmonary atresia ☐ Pulmonary atresia, IVS ☐ Pulmonary atresia, VSD (Including TOF, PA) ☐ Pulmonary atresia, VSD-MAPCA
	Ebstein's Anomaly □ Ebstein's anomaly
	Hypoplastic Left Heart Syndrome (HLHS) ☐ Hypoplastic left heart syndrome
	Single Ventricle ☐ Single ventricle, DILV ☐ Single ventricle, DIRV ☐ Single ventricle, Mitral atresia ☐ Single ventricle, Unbalanced AV canal ☐ Single ventricle, Heterotaxia syndrome ☐ Single ventricle, Other ☐ Single ventricle + Total anomalous pulmonary venous connection (TAPVC)
	ricuspid Artesia
	☐ Single ventricle, Tricuspid atresia
	Transposition of the Great Arteries (TGA) □ d-TGA, IVS □ d-TGA, IVS-LVOTO □ d-TGA, VSD □ d-TGA, VSD-LVOTO
	Double Outlet Right Ventricle (DORV) □ DORV, VSD type □ DORV, TOF type □ DORV, TGA type □ DORV, Remote VSD (uncommitted VSD) □ DORV + AVSD (AV Canal) □ DORV, IVS □ DORV, Remote VSD (uncommitted VSD)
	Coarctation of Aorta
	 □ Coarctation of aorta □ Aortic arch hypoplasia □ VSD + Aortic arch hypoplasia □ VSD + Coarctation of aorta

	 Interrupted Arch □ Interrupted aortic arch □ Interrupted aortic arch + VSD □ Interrupted aortic arch + AP window (aortopulmonary window)
	Aortic Valve Disease ☐ Aortic Stenosis receiving intervention in first 30 days of life ☐ Pulmonary Stenosis receiving intervention in the first 30 days of life
Was a Prenatal Echocardiogram Completed?	[IF YES] Did the Prenatal Echo findings suggest CCHD? ☐ Yes
☐ Yes ☐ No ☐ Unknown	□ No □ Unknown

X-Linked Adrenoleukodystrophy (X-ALD)

inal diagnosis as determined by a metabolic ger X-Linked Adrenoleukodystrophy (in males) Contiguous ABCD1 DXS1357E deletion synd X-Linked Adrenoleukodystrophy (in females) Peroxisomal Disorder Acyl-CoA Oxidase Deficiency D-Bifunctional Protein Deficiency Dyamin-like protein 1 (DLP1) ABDC5 Non-peroxisomal Disorder Uncertain Type/Onset Unknown	rome (CADDS)
Diagnos	tic Workup
Was plasma VLCFA tested? ☐ Yes ☐ No ☐ Unknown	[IF YES] What was the VLCFA level? □ Elevated □ Slightly elevated □ Normal □ Low □ Unknown "Elevated" signifies in pathogenic range, while "slightly elevated" signifies above normal, but not in the pathogenic range
Clinical symptoms? Present Not present Not present at birth Unknown	Symptoms may include: neonatal hypotonia, neonatal seizures, liver disease, neonatal cholestasis, sensorineural deafness, failure to thrive, craniofacial abnormalities
Was plasmalogen testing done? ☐ Yes ☐ No ☐ Unknown	[IF YES] Plasmalogen level? □ Normal □ Low □ Unknown

Family History done?	[IF YES]
☐ Yes ☐ No ☐ Unknown	Family history results: ☐ Family history present ☐ Family VLCFA studies suggestive of X-linked ALD ☐ Family history not present ☐ Unknown
Were fibroblast studies done? ☐ Yes ☐ No ☐ Unknown	[IF YES] Fibroblast study results: □ Consistent with Zellweger Spectrum Disorder □ Consistent with Acyl-CoA Oxidase Deficiency □ Consistent with D-Bifunctional Protein □ Consistent with DLP1 □ Consistent with ABCD5 □ Unknown
Molecul	ar Genetics
Was mutation analysis done? ☐ Yes ☐ No ☐ Unknown	[IF YES] What genes were included in the mutation analysis? (select all that apply) □ ABCD1 □ PEX1 □ ACOX1 □ HSD17B4 □ 1 of the 7 known genes for Aicardi-Goutières Syndrome □ Other gene
	 [IF ABCD1] Check the type of variations found: □ Pathogenic variant □ Deletion/duplication identified □ No mutation on sequencing, deletion/duplication not done □ No mutation on sequencing, deletion/duplication not toned; rule out other disorders of peroxisomal beta oxidation □ Variant of unknown significance □ Deletion identified in ABCD1 and DXS1357 □ Unknown

[IF	F PEX1] Check the type of variations found on:
AI	llele 1
	Variant known to be disease causing Variant of unknown significance Variant of unknown significance (predicted to be pathogenic) Wild Type (normal) Unknown
Al	lele 2
	Variant known to be disease causing Variant of unknown significance Variant of unknown significance (predicted to be pathogenic) Wild Type (normal) Unknown
[IF	FACOX1] Check the type of variations found on:
Al	lele 1
	Variant known to be disease causing Variant of unknown significance Variant of unknown significance (predicted to be pathogenic) Wild Type (normal) Unknown
AI	llele 2
	Variant known to be disease causing Variant of unknown significance Variant of unknown significance (predicted to be pathogenic) Wild Type (normal) Unknown

[1	F HSD17b4]Check the type of variations found
0	n:
A	llele 1
	 Variant known to be disease causing Variant of unknown significance Variant of unknown significance (predicted to be pathogenic) Wild Type (normal) Unknown
A	llele 2
	 Variant known to be disease causing Variant of unknown significance Variant of unknown significance (predicted to be pathogenic) Wild Type (normal) Unknown
	F 1 of the 7 known genes for Aicardi-Goutières yndrome] Check the type of variations found on:
A	llele 1
	 Variant known to be disease causing Variant of unknown significance Variant of unknown significance (predicted to be pathogenic) Wild Type (normal) Unknown
A	llele 2
	 Variant known to be disease causing Variant of unknown significance Variant of unknown significance (predicted to be pathogenic) Wild Type (normal) Unknown

[IF	Other Gene Selected]
Ot	ther Gene Name;
Ch	neck the type of variations found on:
Al	lele 1
	Variant known to be disease causing Variant of unknown significance Variant of unknown significance (predicted to be pathogenic) Wild Type (normal) Unknown
Al	lele 2
	Variant known to be disease causing Variant of unknown significance Variant of unknown significance (predicted to be pathogenic) Wild Type (normal) Unknown

Spinal Muscular Atrophy (SMA)

Diagnostic Workup	
Newborn Screen Molecular Test for SMN1?	[IF YES]
□ Yes	What was the result?
□ No □ Unknown	 □ Zero copies of SMN1 (presumed homozygous deletion/conversion)* □ Zero copies of SMN1 (presumed homozygous deletion/conversion)* - observed on two independently collected NBS specimens □ 2 pathogenic variants □ 2 pathogenic variants observed on two independently collected NBS specimens □ 1 pathogenic variant and 1 variant of unknown significance □ 2 variants of unknown significance □ Unknown/ Not Done/Screen Negative
	* true deletion of exon 7 (or larger) or for which there has been a gene conversion of exon 7 (or
Newborn Screen Molecular Test for SMN2?	[IF YES]
□ Yes	SMN2 Copy Number?
□ No	□ One
□ Unknown	□ Two
	☐ Two or more
	☐ Unknown/Not Done
Post-Newborn Screen Molecular Test for	[IF YES]
SMN1?	What was the result?
□ Yes	☐ Zero copies of <i>SMN1</i> (presumed homozygous
□ No	deletion/conversion)*
□ Unknown	 □ Zero copies of SMN1 (presumed homozygous deletion/conversion)* - observed on two independently collected specimens □ 2 pathogenic variants □ 2 pathogenic variants observed on two independently collected specimens □ 1 pathogenic variant and 1 variant of unknown significance □ 2 variants of unknown significance □ Unknown/ Not Done/Screen Negative
	* true deletion of exon 7 (or larger) or for which there has been a gene conversion of exon 7 (or more)

Post-Newborn Screen Molecular Test for	[IF YES]
SMN2?	SMN2 Copy Number?
□ Yes	□ One
□ No	☐ Two
□ Unknown	☐ Two or more
	☐ Unknown/Not Done
Parental Molecular Testing Family	[IF YES]
History/Parental Genetic Testing?	What was the result?
☐ Yes	☐ Phasing is complete and confirms that variants
□ No	are in trans or both parents are known to be
☐ Unknown	carriers of the pathogenic variants identified
	☐ Both parents are known carriers of <i>SMN1</i>
	deletion
	☐ Unknown/Not Done
Clinical symptoms?	Symptoms may include: Electromyography
□ Present	evidence of motor neuron disease, Absent reflexes,
□ Not present	Fasciculations, Feeding difficulty, Hypotonia,
☐ Unknown	Respiratory Difficulty, Weakness
Was treatment started?	[IF YES]
□ Yes	Type of treatment? (Check all that apply)
□ No	☐ Gene Therapy
☐ Unknown	□ Nusinersin
	☐ Other: please describe
	☐ Unknown